Modeling of trough plasma bismuth concentrations

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 25, Issue 1, 1997, Pages 79-106

  Bennett, J E ^a   Wakefield, J C ^a   Lacey, L F ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bayesian analysis; Bismuth pharmacokinetics; Covariate modeling; Gibbs sampler; Population pharmacokinetics; Predictive distributions; Ranitidine bismuth citrate; Simulation

Indexed keywords

BISMUTH; RANITIDINE BISMUTH CITRATE;

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; MODEL; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; SIMULATION;

BAYES THEOREM; BISMUTH; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MODELS, BIOLOGICAL; RANITIDINE;

EID: 0030680115     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025771811143     Document Type: Article

References (23)

1. G. A. Pipkin, J. G. Mills, L. Kler, J. S. Dixon, and J. R. Wood. The safety of ranitidine bismuth citrate in control clinical trials. Pharmacoepidemiol. Drug Safety (in press).
2. H. P. Wijinand. Pharmacokinetic model equations for the one- and two-compartment models with first-order processes in which absorption and exponential elimination or distribution rate constants are equal. J. Pharmacokin. Biopharm. 16:109-128 (1988).
3. J. C. Wakefield. The Bayesian analysis of population pharmacokinetic models. J. Am. Statist. Assoc. 91:306-319 (1996).
4. J. C. Wakefield, A. F. M. Smith, A. Racine-Poon, and A. E. Gelfand. Bayesian Analysis of Linear and Non-linear Population Models using the Gibbs Sampler. Appl. Statist. 41:201-221 (1994).
5. J. E. Bennett and J. C. Wakefield. A comparison of a Bayesian population method with two methods as implemented in commercially-available software. J. Pharmacokin. Biopharm. 24:403-432 (1996).
6. L. Z. Benet. Safety and pharmacokinetics: Colloidal bismuth subcitrate. Scand. J. Gastroenterol. 26:185:29-35 (1991).
7. L. F. Lacey, S. Lettis, J. Douglas, and A. Duggan. Effect on trough plasma concentrations in duodenal ulcer patients following co-prescription of ranitidine bismuth citrate (GR122311X) with clarithromycin or amoxycillin. Pharm. Res. 12 (Suppl. 9):S394 (1995).
8. L. F. Lacey, N. M. Frazer, O. N. Keene, and J. T. L. Smith. Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium ditcitrato bismuthate TDB. Eur. J. Clin. Pharmacol. 47:177-180 (1994).
9. M. Rowland and T. N. Tozer. Clinical Pharmacokinetics: Concepts and Applications, 2nd ed., Lea and Febiger, Philadelphia, 1989.
10. J. C. Wakefield and J. E. Bennett. The Bayesian modelling of covariates for population pharmacokinetic models. J. Am. Statist. Assoc. 91:917-927 (1996).
11. K. D. Bardhan, C. P. M. Dekkers, A. Nowak, O. B. Shaffalitzky de Muckadell, K. Schutze, G. Tildesley, L. Kler, J. K. Forster, and L. F. Lacey. GR122311X (ranitidine bismuth citrate) A new drug for the treatment of duodenal ulcer. Gastroenterology 106 (4 Part 2): A46 (1994).
12. J. C. Douglas, N. Lotay, L. Kler, and L. F. Lacey. Trough plasma bismuth concentrations during long-term treatment with ranitidine bismuth citrate. Gut. 39 (Suppl. 3): A49 (1996).
13. A. Gelman, J. B. Carlin, H. S. Stern, and D. B. Rubin. Bayesian Data Analysis, Chapman and Hall, London, 1995.
14. J. C. Wakefield. An expected loss approach to the design of dosage regimens via sampling-based methods. Statistician 43:13-29 (1994).
15. J. C. Wakefield. Bayesian individualization via sampling-based methods. J. Pharmacokin. Biopharm. 24:103-131 (1996).
16. A. F. M. Smith and G. O. Roberts. Bayesian computations via the Gibbs sampler and related Markov chain Monte Carlo methods. J. Roy. Statist. Soc. B 55:3-23 (1993).
17. W. R. Gilks, D. G. Clayton, D. J. Spiegelhalter, N. G. Best, A. J. McNeil, L. D. Sharples, and A. J. Kirby. Modelling complexity applications of Gibbs sampling in medicine. J. Roy. Statist. Soc. B 55:39-52 (1993).
18. L. Tierney. Markov chains for exploring posterior distributions. Ann. Statist. 22:1701-1762 (1994).
19. J. E. Bennett, A. Racine-Poon, and J. C. Wakefield. Markov chain Monte Carlo for nonlinear hierarchical models. In W. R. Gilks, S. Richardson, and D. J. Spiegelhalter (eds.), Markov Chain Monte Carlo in Practice, Chapman and Hall, London. 1995.
20. W. R. Gilks, N. G. Best, and K. K. C. Tan. Adaptive rejection Metropolis sampling within Gibbs sampling. Appl. Statist. 44:455-472 (1995).
21. N. G. Best, K. K. C. Tan, W. R. Gilks, and D. J. Spiegelhalter. Estimation of population pharmacokinetics using the Gibbs sampler. J. Pharmacokin. Biopharm. 23:407-424 (1995).
22. J. C. Wakefield and A. Racine-Poon. An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation. Statist. Med. 14:971-986 (1995).
23. A. Racine-Poon and J. C. Wakefield. Bayesian analysis of population pharmacokinetic and instantaneous pharmacodynamic relationships. In D. Berry and D. Stangl, (eds.), Bayesian Biostatistics, Marcel Dekker, New York, 1995.